[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350296-105":59,"doc-detail-350296-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","assessment-of-methylated-bcat1-and-ikzf1-circulating-tumor-dna-as-a-prognostic-biomarker-in-esophagogastric-adenocarcinomas","Assessment of methylated BCAT1 and IKZF1 circulating tumor DNA as a prognostic biomarker in esophagogastric adenocarcinomas","","Study objective: evaluate methylated circulating tumor DNA (ctDNA) biomarkers as prognostic tools in esophageal and gastric cancers. Plasma-derived circulating cell-free DNA from 122 esophagogastric cancer patients, collected before treatment, was assayed for methylated BCAT1 and IKZF1. Test positivity was linked to clinicopathologic features, while recurrence-free survival (RFS) and overall survival (OS) were analyzed using Cox regression. Methylated BCAT1/IKZF1 was detected in 54.9% (67/122). Positive ctDNA predicted worse RFS in remission and worse OS in all patients, independent of stage.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/assessment-of-methylated-bcat1-and-ikzf1-circulating-tumor-dna-as-a-prognostic-biomarker-in-esophagogastric-adenocarcinomas/350296/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/assessment-of-methylated-bcat1-and-ikzf1-circulating-tumor-dna-as-a-prognostic-biomarker-in-esophagogastric-adenocarcinomas/350296.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main aim?","Question",{"text":112,"@type":113},"To evaluate the prognostic value of methylated ctDNA biomarkers BCAT1 and IKZF1 in esophageal and gastric cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was methylated ctDNA measured?",{"text":117,"@type":113},"Circulating cell-free DNA was isolated from pre-treatment plasma from 122 patients and assayed for methylated BCAT1 and IKZF1.",{"name":119,"@type":110,"acceptedAnswer":120},"What prognostic impact did a positive ctDNA result show?",{"text":121,"@type":113},"A positive diagnosis ctDNA result was associated with worse recurrence-free survival in patients considered in remission and worse overall survival in all patients, independent of stage and other clinical variables.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350296,1790442190,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Diseases of the Esophagus (2026), 39, 1–12 [https://doi.org/10.1093/dote/doag048](https://doi.org/10.1093/dote/doag048)  \nOriginal Article  \nAssessment of methylated BCAT1 and IKZF1 circulating tumor DNA as a prognostic biomarker in esophagogastric adenocarcinomas  \nMei Mei Chan, 1 Amitesh C. Roy, 1 David I. Watson, 2 , 3 Tim Bright,2 , 3 Lorraine Sheehan-Hennessy,3 Graeme P. Young,3 Damian Hussey,2 , 3 Susanne K. Pedersen,3 Jean M. Winter,3 Erin L. Symonds, 3 , 4 1 Department of Oncology, Flinders Medical Centre, Southern Adelaide LocalHealth Network, BedfordPark, South Australia, Australia, 2 Department of Surgery, Flinders Medical Centre, Southern Adelaide Local Health Network, BedfordPark, South Australia, Australia, 3 Flinders Health andMedicalResearch Institute, College of Medicine and Public Health, Flinders University, BedfordPark, South Australia, Australia, and 4 Department of Gastroenterology, Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia  \nSUMMARY. Esophagogastric adenocarcinomas have poor survival, and accurate prognosis assessment is required to guide appropriate treatment. Pre-treatment planning can be challenging and would benefit from non-invasive prognostic tools. Methylated circulating tumor DNA (ctDNA) has prognostic value in colorectal cancer. The aim of the study was to evaluate the prognostic value of methylated ctDNA biomarkers in esophageal and gastric cancers. Circulating cell free DNA, isolated from plasma collected prior to treatment from 122 patients diagnosed with esophagogastric cancer was assayed for methylated BCAT1 and IKZF1. Test positivity was assessed against clinicopathological features, and prognostic factors associated with recurrence-free survival (RFS) and overall survival (OS) were investigated with Cox regression analysis. Methylated BCAT1/IKZF1 DNA was detected in 54.9%(67/122) of patients following a diagnosis of esophagogastric cancer. Advanced disease had higher detection rates, with a significant association between test positivity and pathological node-positive disease (odds ratio [OR] for pN2: 5.63, 95% CI 1.27–24.86, P =0.02), and metastatic disease (OR 4.92, 95% CI 1.94–12.47, P \u003C0.01). A positive ctDNA result at diagnosis was associated with worse RFS for individuals considered in remission (hazard ratio [HR] 4.49, 95% CI 1.48–13.67, P \u003C0.01), and a worse OS in all patients (HR 3.64, 95% CI 1.73–7.68, P \u003C 0.01), independent of stage and other clinical variables, compared to a negative ctDNA result. Detection of circulating methylated BCAT1/IKZF1 DNA is a promising prognostic biomarker in esophagogastric cancers. Prospective studies are warranted to investigate the utility of methylated BCAT1/IKZF1 for monitoring treatment response and for risk stratification to guide adjuvant therapeutic decisions.  \nKEY WORDS: biomarker, circulating tumor DNA, epigenetic alteration, esophagogastric cancer, risk stratify.  \nAddress correspondence to: Dr Erin L. Symonds, PhD, Bowel Health Service, Level 3, Flinders Centre for Innovation in Cancer, Bedford  \nPark, South Australia 5042, Australia. Email: [erin.symonds@flinders.edu.au](erin.symonds@flinders.edu.au)  \nSpecific author contributions: Mei Mei Chan (Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing—original draft, Writing—review & editing), Amitesh Roy (Conceptualization, Funding acquisition, Investigation, Resources, Supervision, Writing—review & editing), David Watson (Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing—review & editing), Tim Bright (Project administration, Resources, Supervision, Writing—review & editing), Lorraine Sheehan-Hennessy (Investigation, Project administration, Resources, Writing—review & editing), Graeme P. Young (Conceptualization, Funding acquisition, Methodology, Writing—review & editing), Damian Hussey (Conceptualizat","cbCainY2eIf9dwwO","https://ap.wps.com/l/cbCainY2eIf9dwwO","pdf",1299920,12,"English","# Summary\n# Introduction\n## Study rationale and clinical need for prognosis assessment\n# Methods and analysis\n## Biomarker testing and survival modeling","[{\"question\":\"What was the study’s main aim?\",\"answer\":\"To evaluate the prognostic value of methylated ctDNA biomarkers BCAT1 and IKZF1 in esophageal and gastric cancers.\"},{\"question\":\"How was methylated ctDNA measured?\",\"answer\":\"Circulating cell-free DNA was isolated from pre-treatment plasma from 122 patients and assayed for methylated BCAT1 and IKZF1.\"},{\"question\":\"What prognostic impact did a positive ctDNA result show?\",\"answer\":\"A positive diagnosis ctDNA result was associated with worse recurrence-free survival in patients considered in remission and worse overall survival in all patients, independent of stage and other clinical variables.\"}]","Assessment of methylated BCAT1 and IKZF1 circulating tumor DNA as a prognostic biomarker in esophagogastric adenocarcinomas | PDF",1790088296,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d97870d048c54dd6299714573ef4366.webp",983,1296,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7d284239ffa18fc2dae2bbc8430460e.webp",982,1294,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e75d7b1505aa73b3560d27c04401ff1d.webp",981,1293,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ab94a3a069ea9705eb40ca02b977071.webp",980,1292]